How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution

PURPOSE: Gefitinib was introduced in 2002 for treatment of non-small cell lung cancer (NSCLC); however, it is not clear whether its use in daily practice has changed the outcome of patients. The purpose of this study is to evaluate the question of how molecular understanding regarding gefitinib and...

Descripción completa

Detalles Bibliográficos
Autores principales: Keam, Bhumsuk, Kim, Dong-Wan, Park, Jin Hyun, Lee, Jeong-Ok, Kim, Tae Min, Lee, Se-Hoon, Chung, Doo Hyun, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804729/
https://www.ncbi.nlm.nih.gov/pubmed/24155676
http://dx.doi.org/10.4143/crt.2013.45.3.178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804729/
https://www.ncbi.nlm.nih.gov/pubmed/24155676
http://dx.doi.org/10.4143/crt.2013.45.3.178

Ejemplares similares